Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction

May 6, 2022
By Marisa C. Weiss
Adam Leitenberger
  • Frank J. Della Croce
  • Melissa Bollmann Jenkins
  • Donna-Marie Manasseh

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 24

Background

Informed consent is a fundamental ethical and legal requirement to ensure that patients are aware of the risks and benefits of surgical interventions. An effective informed consent process provides adequate information, prioritizes patient comprehension, and facilitates shared decision-making with the goal of optimal patient outcomes and satisfaction.


Objective

We sought to characterize the informed consent process for patients undergoing breast cancer surgery and investigate the extent to which certain elements of the process are associated with patient satisfaction.


Methods

Breastcancer.org visitors and registered online community members in the United States were invited to complete an online survey between August 5 and October 2, 2021. The survey included multiple-choice and rank-order questions about their informed consent and breast cancer surgery experience. All data were deidentified and analyzed in aggregate.


Results

The survey was completed by 2009 adult women diagnosed with breast cancer (mean age, 58 years; 85% White) who had surgery within the past 5 years (mean time since surgery, 17 months). Overall, 42% reported that they were alone when they signed the informed consent form, which was more common during vs before the pandemic (47% vs 34%; P <.05). Patients who were not alone were more likely to report being very/extremely satisfied with their surgical outcomes (61% vs 39%; P <.05). Patients reported being most comfortable when their surgeon was the health care provider who spoke with them before they signed the consent form (91%), as compared with a nurse (79%) or other health care provider (64%). Patients were also more satisfied with surgical outcomes when they felt their surgeons effectively informed them about their surgical options, adequately answered their questions, provided written educational materials, or referred them to reputable online sources. Of patients who were very/extremely satisfied with their surgical outcomes, 92% felt very/extremely well informed at the end of their surgical consultation process.


Conclusions

Patients with breast cancer reported higher satisfaction with surgical decisions when they had a positive informed consent experience that prioritized patient education, comfort, and engagement with the surgeon. This survey highlights the importance of investing in the informed consent process to facilitate shared decision-making for better patient satisfaction with surgical outcomes.

Author Affiliations:

Marisa C. Weiss,1 Adam Leitenberger,2 Frank J. Della Croce,3 Melissa Bollmann Jenkins,4 Donna-Marie Manasseh5

1Chief medical officer/founder, Breastcancer.org; Director of Breast Radiation Oncology, Lankenau Medical Center, Wynnewood, PA
2Editorial director, Breastcancer.org.

3Founding partner, Center for Restorative Breast Surgery, New Orleans, LA
4Community director, Breastcancer.org
5Chief of breast surgery, Maimonides Breast Cancer Center, Brooklyn, NY

Download Issue PDFDownload PDF
Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content
Advertisement

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

Philippe Aftimos;Javier Cortes;Francois Clement Bidard;Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;Patrick Neven, MD, PhD
April 28th 2023
Article

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

Talal Ahmed;Daniel Stover;Adam Hockenberry;Matthew Mackay;Raphael Pelossof;Halla Nimeiri;James L. Chen;Rotem Ben-Shachar;Massimo Cristofanilli, MD
April 28th 2023
Article

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

Sabah Alaklabi;Joseph Elijah;Arya Mariam Roy;Adrienne Groman;Shipra Gandhi
April 28th 2023
Article

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

Jamil Asselah;Cynthia X. Ma, MD, PhD;Zbigniew Nowecki;Robert Huisden;Ross Stewart;Petra Vuković;Peter Schmid, MD
April 28th 2023
Article

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

Alexandra Guarin;Katie Mycock;Gary Milligan;Gavin Taylor-Stokes;Christian Atkinson
April 28th 2023
Article

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Aditya Bardia, MD, MPH;Francois Clement Bidard;Patrick Neven, MD, PhD;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Philippe Aftimos;Javier Cortes;Simona Scartoni;Nassir Habboubi;Virginia Kaklamani, MD, DSc
April 28th 2023
Article
Related Content
Publications
Advertisement

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

Philippe Aftimos;Javier Cortes;Francois Clement Bidard;Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;Patrick Neven, MD, PhD
April 28th 2023
Article

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

Talal Ahmed;Daniel Stover;Adam Hockenberry;Matthew Mackay;Raphael Pelossof;Halla Nimeiri;James L. Chen;Rotem Ben-Shachar;Massimo Cristofanilli, MD
April 28th 2023
Article

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

Sabah Alaklabi;Joseph Elijah;Arya Mariam Roy;Adrienne Groman;Shipra Gandhi
April 28th 2023
Article

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

Jamil Asselah;Cynthia X. Ma, MD, PhD;Zbigniew Nowecki;Robert Huisden;Ross Stewart;Petra Vuković;Peter Schmid, MD
April 28th 2023
Article

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

Alexandra Guarin;Katie Mycock;Gary Milligan;Gavin Taylor-Stokes;Christian Atkinson
April 28th 2023
Article

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Aditya Bardia, MD, MPH;Francois Clement Bidard;Patrick Neven, MD, PhD;Alberto J. Montero, MD, MBA, CPHQ;Joo Hyuk Sohn;Philippe Aftimos;Javier Cortes;Simona Scartoni;Nassir Habboubi;Virginia Kaklamani, MD, DSc
April 28th 2023
Article
Advertisement
Advertisement
Advertisement
Advertisement
x
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.